A randomized, placebo-controlled, blinded phase 1 study investigating a novel inactivated, Vero cell-culture derived Zika virus vaccine
Journal of Travel Medicine · 2024
DOI: 10.1093/jtm/taac127 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Journal of Travel Medicine, 2024. Verfasst von Nina V Wressnigg und 8 weiteren Autor:innen. Beteiligte Einrichtung: Valneva Austria GmbH, Vienna, Austria. Hauptthemen laut MEDLINE: Zika Virus, Zika Virus Infection, Viral Vaccines, Vaccines, Inactivated. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Emergent Biosolutions, Valneva Austria GmbH.
Abstract (Originalsprache)
Background
Zika virus (ZIKV) is an emerging public health threat, rendering development of a safe and effective vaccine against the virus a high priority to face this unmet medical need. Our vaccine candidate has been developed on the same platform used for the licensed vaccine IXIARO®, a vaccine against Japanese Encephalitis virus, another closely related member of the Flaviviridae family.
Methods
Between 24 February 2018 and 16 November 2018, we conducted a randomized, observer-blinded, placebo controlled, single center phase 1 study to assess the safety and immunogenicity of an adjuvanted, inactivated, purified whole-virus Zika vaccine candidate in the USA. A total of 67 healthy flavivirus-naïve adults aged 18–49 years were randomly assigned to one of five study arms to receive two immunizations of either high dose or low dose (6 antigen units or 3 antigen units) with both dose levels applied in two different immunization regimens or placebo as control.
Results
Our vaccine candidate showed an excellent safety profile independent of dose and vaccination regimen with predominantly mild adverse events (AEs). No serious AE has been reported. The ZIKV vaccine induced neutralizing antibodies in all tested doses and regimens with seroconversion rates up to 85.7% (high dose), which remained up to 40% (high dose) at 6 months follow-up. Of note, the rapid regimen triggered a substantial immune response within days.
Conclusions
The rapid development and production of a ZIKV vaccine candidate building on a commercial Vero-cell manufacturing platform resulted in a safe and immunogenic vaccine suitable for further clinical development. To optimize antibody persistence, higher doses and a booster administration might be considered.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Valneva Austria GmbH, Vienna, Austria.
Förderung
- Emergent Biosolutions
- Valneva Austria GmbH
Zitieren
APA
Wressnigg, N. V., Hochreiter, R., Schneider, M., Obersriebnig, M. J., Bézay, N. I., Lingnau, K., Ramljak, I. Č., Dubischar, K. L., & Eder-Lingelbach, S. (2024). A randomized, placebo-controlled, blinded phase 1 study investigating a novel inactivated, Vero cell-culture derived Zika virus vaccine. Journal of Travel Medicine. https://doi.org/10.1093/jtm/taac127
Vancouver
Wressnigg NV, Hochreiter R, Schneider M, Obersriebnig MJ, Bézay NI, Lingnau K, et al. A randomized, placebo-controlled, blinded phase 1 study investigating a novel inactivated, Vero cell-culture derived Zika virus vaccine. Journal of Travel Medicine. 2024. doi:10.1093/jtm/taac127
BibTeX
@article{Wressnigg2024,
author = {Wressnigg, Nina V and Hochreiter, Romana and Schneider, Martina and Obersriebnig, Michaela J and Bézay, Nicole I and Lingnau, Karen and Ramljak, Irena Čorbić and Dubischar, Katrin L and Eder-Lingelbach, Susanne},
title = {A randomized, placebo-controlled, blinded phase 1 study investigating a novel inactivated, Vero cell-culture derived Zika virus vaccine},
journal = {Journal of Travel Medicine},
year = {2024},
doi = {10.1093/jtm/taac127}
}
EUVIMED